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Background. We investigated the association between blood pressure control and common cardiometabolic risk factors from a
global and regional perspective. Methods. In the present analysis of a large cross-sectional i-SEARCH study, 17.092 outpatients
receiving antihypertensive treatment were included in 26 countries. According to clinical guidelines for the management of arterial
hypertension, patients were classiﬁed based on the level of seated systolic/diastolic blood pressure (SBP/DBP). Uncontrolled
hypertensionwasdeﬁnedasSBP/DBP ≥140/90mmHgfornon-diabetics,and ≥130/80mmHgfordiabetics.Results.Overall,mean
agewas63.1years,52.8%weremale,andmeanBMIwas28.9kg/m2.MeanSBP/DBPwas148.9/87.0mmHg,and76.3%ofpatients
haduncontrolled hypertension.Diabetes was present in29.1% withmean HbA1cof 6.8%.Mean LDL-cholesterolwas 3.2mmol/L,
HDL-cholesterol 1.3mmol/L, and triglycerides 1.8mmol/L; 49.0% had hyperlipidemia. Patients with uncontrolled hypertension
had a higher BMI (29.4 versus 28.6kg/m2), LDL-cholesterol (3.4 versus 3.0mmol/L), triglycerides (1.9 versus 1.7mmol/L),
and HbA1c (6.8 versus 6.7%) than those with controlled blood pressure (P<0.0001 for all parameters). Conclusions.A m o n g
outpatients treated for arterial hypertension, three quarters had uncontrolled blood pressure. Elevated SBP/DBP and uncontrolled
hypertension were associated with increasing BMI, LDL-cholesterol, triglycerides, and HbA1c, both globally and regionally.
1.Introduction
Arterial hypertension represents a major cause of cardiovas-
cular morbidity and mortality, and aﬀects approximately 1
billion individuals worldwide [1, 2]. Despite the availability
of eﬃcient nonpharmacological and pharmacological thera-
pies, blood pressure control rates are largely unsatisfactory,
mostly due to underdiagnosis and undertreatment [3]. Fur-
thermore, arterial hypertension is frequently clustered with
other metabolic disorders, such as an elevated body mass
index (BMI), waist circumference (WC), fasting glucose, tri-
glycerides(TG),andHDL-cholesterol—allofwhichareasso-
ciated with adverse cardiovascular outcomes [4–7]. There-
fore, international guidelines mandate not only an assess-
ment of the global cardiovascular risk, but also a risk-based
approach to antihypertensive therapy [8]. Apart from the
impact of the association of an elevated blood pressure with
metabolicdisordersonpatient’scardiovascularrisk,thereare
also implications from a therapeutic perspective. Recent data
have shown independent antihypertensive eﬀects of statins
in patients with hypertension and hypercholesterolemia, and
an association of blood pressure lowering with a decrease
in the antioxidative activity of HDL-cholesterol [9, 10].
These data illustrate not only a potential cross-talk between2 Cardiology Research and Practice
diﬀerent biochemical pathways, involved in the pathogenesis
of atherosclerotic disease, but also the ability of pharma-
cological treatments to act on several risk factors at the
same time. Especially in light of the low blood pressure
control rates worldwide, it appears to be important to have
a deeper understanding of the association of blood pressure
with relevant metabolic risk factors and cardiovascular risk
markers. The present analysis aims to investigate the associ-
ation of blood pressure control with several metabolic risk
factors/cardiovascular risk indicators, and to gain insights
into regional/ethnical diﬀerences of these associations from
a large international survey, conducted in more than 20.000
patients with arterial hypertension.
2. Methods
A large cross-sectional International Survey Evaluating
microAlbuminuria Routinely by Cardiologists in patients
with Hypertension (i-SEARCH) study was conducted in
2005-2006 in cardiology outpatient clinics in 26 countries
world-wide as described previously [11]. 21.794 patients,
aged ≥18 years with currently treated or newly diagnosed
arterial hypertension, were enrolled into the study. In all
patients, urinary dipstick screening was performed and the
prevalence of microalbuminuria (MAU) was determined.
Furthermore,informationonpatientdemographics,anthro-
pometric measures, cardiovascular risk factors, metabolic
parameters, comorbid conditions, and cardiovascular drug
therapy was collected. The present analysis was performed
in 17.092 patients receiving antihypertensive treatment.
According to contemporary clinical guidelines for the
management of arterial hypertension [8], patients were
classiﬁed based on the level of seated systolic/diastolic blood
pressure (SBP/DBP) measured at rest on day of study visit.
For each level of SBP (<120, 120-139, 140-159, 160-179,
≥180mmHg)andDBP(<90,90-99,100-109, ≥110mmHg),
the association with the following indicators of car-
diometabolic risk was determined: BMI (kg/m2), WC (cm),
diabetes mellitus (%), HbA1c (%), LDL/HDL-cholesterol
(mg/dL),triglycerides(mg/dL),andC-reactiveprotein(CRP,
mg/dL). Furthermore, cardiometabolic risk was determined
according to blood pressure control. Uncontrolled hyper-
tension was deﬁned as SBP/DBP ≥140/90mmHg for non-
diabetic and ≥130/80mmHg for diabetic patients.
All analyses were performed both globally and separately
for the following 5 geographical regions: Northern Europe
(Belgium, Germany, Sweden, Switzerland), Southern Europe
(Greece, Italy, Spain, Turkey), North America (Canada),
Middle East (Kuwait, Lebanon, Qatar, Saudi Arabia, United
Arab Emirates) and Asia (Hong Kong, Indonesia, Korea, Sin-
gapore,Taiwan,Thailand,Vietnam).Theanalysispopulation
comprised patients with no missing data for SBP/DBP and
the respective metabolic parameter. A linear model was used
toestimatetheleastsquaremeansofBMI,WC,HbA1c,LDL-
cholesterol,HDL-cholesterol,triglycerides,andCRPforeach
level of SBP/DBP and by region. The model was adjusted
for age and gender (BMI, WC, and CRP); for age, gender,
and antidiabetic treatment (HbA1c); and for age, gender,
and the presence of diabetes (LDL- and HDL-cholesterol,
triglycerides). A logistic regression analysis was conducted
to estimate the prevalence of diabetes for each level of
SBP/DBPandregion,adjustedforageandgender(predictive
marginal probabilities). Continuous variables are depicted as
adjusted means (least square means) ± standard deviations
and categorical variables as percentages (95% conﬁdence
intervals).
3. Results
3.1. Cardiometabolic Risk Proﬁle. Overall, mean patient age
was 63.1 years out of which 52.8% were male. Mean
SBP/DBP was 148.9/87.0mmHg, and 76.3% of patients
had uncontrolled blood pressure. Diabetes was present
in 29.1% of patients with mean HbA1c of 6.8%. Mean
LDL-cholesterol was 3.2mmol/L, mean HDL-cholesterol
1.3mmol/L, and mean triglycerides 1.8mmol/L, and 49.0%
of patients had hypercholesterolemia. MAU was present in
58.8% of patients, and mean CRP was 0.92mg/dL. 38.8%
of patients were present or past smokers, and 28.6% had a
family history of a myocardial infarction. For concomitant
cardiovasculardiseaseandregionaldistributionofindividual
parameters, see Table 1.
3.2. Blood Pressure and BMI/WC. Globally, the mean BMI
was higher in patients with SBP ≥180 versus <120mmHg
(29.5 versus 28.2kg/m2), in patients with DBP ≥110 versus
<90mmHg (30.3 versus 28.5kg/m2), and in patients with
uncontrolled versus controlled blood pressure (29.4 versus
28.6kg/m2)( P<0.0001 for all parameters). Mean WC
was higher in patients with SBP ≥180 versus <120mmHg
(101.2 versus 97.5cm), in patients with DBP ≥110 versus
<90mmHg (103.2 versus 98.8cm), and in patients with
uncontrolled versus controlled blood pressure (100.7 versus
98.8cm) (P<0.0001 for all parameters). By comparing the
association of BMI and WC across the regions, an increase
in BMI with increasing SBP/DBP could be observed for
Northern, Southern Europe and the Middle East region,
whereas in North America and Asia, BMI decreased with
increasing SBP, and increased with DBP (P<0.05 for
all comparisons). Only in Northern and Southern Europe,
uncontrolledversuscontrolledbloodpressurewasassociated
with an increase in BMI (P<0.0001). With increasing
SBP/DBP an increase in WC could be observed for Northern
Europe, Southern Europe, North America, and Middle East
(in the latter only for DBP, P<0.0001), whereas an inverse
relationship between SBP/DBP and WC was observed for
Asia (P<0.0001). For details see Tables 2 and 3.
3.3. Blood Pressure and Diabetes/HbA1c. T h ep r e v a l e n c eo f
diabetes was 28.4% in patients with an SBP <120mmHg and
32.6% in patients with an SBP ≥180mmHg (P<0.0001).
Diabetes was present in 30.9% of patients with a DBP
<90mmHg and 28.1% of patients with a DBP ≥110mmHg
(P<0.0001). There was no diﬀerence in the prevalence
of diabetes in patients with uncontrolled versus controlled
hypertension in the overall population (27.7% versus 30.4%;
P = 0.18). Mean HbA1c increased from 6.7% in patientsCardiology Research and Practice 3
Table 1: Patient characteristics.
Total
(N = 17,092)
Northern Europe
(N = 5,655)
Southern Europe
(N = 6,655)
North America
(N = 1,455)
Middle East
(N = 570)
Asia
(N = 2,757)
Age 63.1 64.9 62.5 65.7 57.1 60.5
Gender (male, %) 52.8 53.0 52.9 56.3 61.0 48.5
BMI (kg/m2) 28.9 29.7 29.2 30.2 29.8 25.9
Waist circumference (cm) 99.7 102.5 100.9 102.6 102.5 89.5
Systolic blood pressure (mmHg) 148.9 151.5 148.6 144.3 156.6 145.1
Diastolic blood pressure (mmHg) 87.0 87.7 87.7 81.4 92.0 85.6
Uncontrolled blood pressure (%)∗ 76.3 82.1 75.6 64.9 87.9 69.5
Diabetes mellitus (%) 29.1 33.9 27.4 30.9 33.8 21.7
HbA1c (%) 6.8 6.7 6.7 6.7 7.9 7.1
LDL cholesterol (mmol/L) 3.2 3.2 3.3 2.6 3.4 3.1
HDL cholesterol (mmol/L) 1.3 1.5 1.3 1.3 1.1 1.3
Triglycerides (mmol/L) 1.8 1.9 1.7 1.7 2.0 1.8
Hyperlipidemia (%) 49.0 53.0 43.3 64.4 56.1 46.1
Smoking (current/past; %) 38.8 36.4 41.8 55.7 44.9 28.5
Family history of MI (%) 28.6 22.0 29.6 40.0 25.5 36.3
Microalbuminuria (%) 58.6 54.3 59.6 53.8 71.6 64.7
CRP (mg/dL) 0.92 1.02 0.91 0.54 0.91 0.49
Coronary artery disease (%) 25.1 21.5 23.7 40.5 30.4 26.4
Congestive heart failure (%) 6.4 6.3 6.7 5.5 8.3 6.0
Atrial ﬁbrillation (%) 9.3 9.5 11.1 11.7 4.7 4.0
Myocardial infarction (%) 31.6 24.4 34.1 41.7 27.9 37.1
Ischemic stroke (%) 5.1 24.7 5.5 5.6 4.4 14.6
Peripheral artery disease (%) 4.6 6.1 5.0 5.7 4.7 0.5
Betablockers (%) 48.7 59.7 40.2 44.8 52.5 48.1
Calcium Antagonists (%) 36.0 30.3 31.9 43.4 36.7 53.6
ACE-Inhibitors (%) 42.3 45.8 42.8 49.5 31.9 32.1
AT1-Rezeptorantagonists (%) 35.8 30.1 41.3 31.1 47.9 34.4
Diuretics (%) 9.9 10.9 10.5 8.0 10.7 7.4
∗Uncontrolled blood pressure was deﬁned as SBP/DBP ≥140/90 in non-diabetic and ≥130/80 in diabetic patients.
with an SBP of <120mmHg to 7.0% in patients with an
SBP of ≥180mmHg (P<0.0001), from 6.8% in patients
with a DBP <90mmHg to 6.9% in patients with a DBP
≥110mmHg (P<0.0027), and from 6.7% in patients
with controlled to 6.8% in patients with uncontrolled blood
pressure (P<0.0001). A signiﬁcant increase in HbA1c
with SBP and DBP was observed in Northern and Southern
Europe, but not in Northern America, Middle East, and Asia.
For details, see Tables 4 and 5.
3.4. Blood Pressure and Lipids. The mean LDL-cholesterol
was higher in patients with SBP ≥180 versus <120mmHg
(3.4 versus 2.9mmol/L), in patients with DBP ≥110 versus
<90mmHg (3.5 versus 3.0mmol/L), and in patients with
uncontrolled versus controlled blood pressure (3.4 versus
3.0mmoL) (P<0.0001 for all parameters). Mean HDL-
cholesterol was 1.3mmol/L, and there was no association
between HDL in patients with uncontrolled versus con-
trolled hypertension (P = 0.13). Triglycerides increased
from 1.5mmol/L in patients with an SBP <120mmHg
to 1.9mmol/L in patients with an SBP ≥180mmHg, and
from 1.7mmol/L in patients with a DBP <90mmHg to
1.9mmol/L in patients with a DBP ≥110mmHg (P<
0.0001forbothparameters).Triglycerideswerealsohigherin
patients with uncontrolled versus controlled blood pressure
(1.9 versus 1.7mmol/L, P<0.0001). The regional com-
parison revealed an increase in LDL-cholesterol as well as
triglycerides with increasing SBP and DBP for all 5 regions,
whereas no association between HDL-cholesterol and blood
pressure levels was observed. For details see Tables 6, 7,
and 8.
3.5. Blood Pressure and CRP. The mean CRP was higher
in patients with SBP ≥180 versus <120mmHg (1.1 versus4 Cardiology Research and Practice
Table 2: Blood pressure and BMI (kg/m2; mean ± SE; adjusted for age, gender).
Total
(N = 16,945)
Northern Europe
(N = 5,621)
Southern Europe
(N = 6583)
North America
(N = 1,423)
Midde East
(N = 567)
Asia
(N = 2,751) P value
SBP (mmHg)
<120 28.2 (0.249) 29.1 (0.487) 28.4 (0.453) 30.1 (0.601) 28.3 (1.467) 26.2 (0.474) <0.0001
120–139 28.5 (0.086) 29.1 (0.168) 28.6 (0.132) 30.4 (0.253) 31.0 (0.647) 26.4 (0.187) <0.0001
140–159 28.8 (0.066) 29.6 (0.108) 29.0 (0.102) 30.2 (0.222) 29.7 (0.370) 25.7 (0.158) <0.0001
160–179 29.5 (0.105) 30.2 (0.169) 29.9 (0.165) 30.2 (0.403) 29.6 (0.474) 25.7 (0.287) <0.0001
≥180 29.5 (0.163) 30.2 (0.249) 30.2 (0.264) 29.1 (0.763) 30.0 (0.629) 25.5 (0.445) <0.0001
P value <0.0001 <0.0001 <0.0001 <0.0001 0.0126 <0.0001
DBP (mmHg)
<90 28.5 (0.063) 29.3 (0.110) 28.6 (0.102) 29.9 (0.176) 29.7 (0.440) 26.0 (0.144) <0.0001
90–99 29.2 (0.082) 30.1 (0.134) 29.4 (0.124) 30.5 (0.342) 29.5 (0.395) 25.7 (0.207) <0.0001
100–109 29.5 (0.113) 30.0 (0.187) 30.2 (0.169) 31.5 (0.548) 30.4 (0.471) 25.9 (0.276) <0.0001
≥110 30.3 (0.227) 30.8 (0.362) 31.0 (0.350) 31.9 (1.286) 30.6 (0.793) 26.3 (0.642) <0.0001
P value <0.0001 <0.0001 <0.0001 <0.0001 0.0157 <0.0001
RR (mmHg)
uncontrolled∗ 29.4 (0.066) 29.9 (0.085) 29.5 (0.082) 30.1 (0.190) 29.8 (0.259) 25.7 (0.132) <0.0001
controlled∗∗ 28.6 (0.061) 28.9 (0.170) 28.4 (0.134) 30.3 (0.239) 30.6 (0.650) 26.2 (0.184) <0.0001
P value <0.0001 <0.0001 <0.0001 <0.0001 0.0080 <0.0001
∗SBP/DBP ≥140/90 in non-diabetic and ≥130/80 in diabetic patients, ∗∗<140/90 in non-diabetic and <130/80 in diabetic patients.
Table 3: Blood pressure and WC (cm ± SD, adjusted for age, gender).
Total
(N = 16,808)
Northern Europe
(N = 5,568)
Southern Europe
(N = 6,505)
North America
(N = 1,435)
Middle East
(N = 553)
Asia
(N = 2,747) P value
SBP (mmHg)
<120 97.5 (0.557) 100.2 (1.028) 98.5 (0.948) 100.9 (1.254) 96.9 (3.078) 89.9 (0.994) <0.0001
120–139 98.5 (0.218) 100.3 (0.400) 99.2 (0.314) 102.1 (0.600) 100.8 (1.536) 90.6 (0.445) <0.0001
140–159 99.6 (0.171) 102.2 (0.268) 100.3 (0.255) 102.5 (0.548) 101.0 (0.923) 89.0 (0.392) <0.0001
160–179 100.9 (0.244) 103.4 (0.373) 102.0 (0.364) 102.4 (0.880) 102.4 (1.070) 89.0 (0.634) <0.0001
≥180 101.2 (0.414) 103.3 (0.603) 103.4 (0.642) 101.3 (1.816) 104.6 (1.528) 89.2 (1.067) <0.0001
P value <0.0001 <0.0001 <0.0001 <0.0001 0.1275 <0.0001
DBP (mmHg)
<90 98.8 (0.154) 101.1 (0.256) 99.5 (0.237) 101.7 (0.405) 100.1 (1.024) 89.9 (0.334) <0.0001
90–99 100.1 (0.198) 103.1 (0.309) 100.5 (0.287) 102.5 (0.782) 100.4 (0.924) 89.0 (0.476) <0.0001
100–109 101.3 (0.305) 102.8 (0.485) 103.4 (0.441) 105.1 (1.417) 105.6 (1.230) 89.5 (0.716) <0.0001
≥110 103.2 (0.607) 105.1 (0.916) 104.1 (0.891) 107.4 (3.250) 105.0 (2.041) 89.7 (1.611) <0.0001
P value <0.0001 <0.0001 <0.0001 <0.0001 0.0012 <0.0001
RR (mmHg)
uncontrolled∗ 100.7 (0.167) 102.7 (0.201) 101.2 (0.195) 102.2 (0.445) 102.1 (0.619) 89.2 (0.311) <0.0001
controlled∗∗ 98.8 (0.149) 100.1 (0.400) 99.0 (0.315) 102.1 (0.559) 100.0 (1.523) 90.2 (0.430) <0.0001
P value <0.0001 <0.0001 <0.0001 <0.0001 0.0882 <0.0001
∗SBP/DBP ≥140/90 in non-diabetic and ≥130/80 in diabetic patients, ∗∗<140/90 in non-diabetic and <130/80 in diabetic patients.
0.7mmol/L), in patients with DBP ≥110 versus <90mmHg
(1.0 versus 0.8mmol/L), and in patients with uncontrolled
versus controlled blood pressure (1.0 versus 0.8mmol/L)
(P<0.0001forallparameters).AnincreaseinCRPwithSBP
and DBP was observed in Northern Europe and Northern
America only. For details see Table 9.
4. Discussion
In the present analysis of a large international study of
patients treated for arterial hypertension, both an elevated
SBP and DBP, and uncontrolled hypertension were associat-
ed with increasing BMI, WC, LDL-cholesterol, triglycerides,Cardiology Research and Practice 5
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Table 6: Blood pressure and LDL-Cholesterol (mmol/L ± SD, adjusted for age, gender, and diabetes).
Total
(N = 11,529)
Northern Europe
(N = 3,723)
Southern Europe
(N = 4,679)
North America
(N = 904)
Middle East
(N = 485)
Asia
(N = 1,738) P value
SBP (mmHg)
<120 2.9 (0.044) 3.0 (0.088) 3.0 (0.076) 2.5 (0.109) 2.8 (0.231) 2.8 (0.093) 0.0003
120–139 3.0 (0.048) 3.1 (0.035) 3.0 (0.028) 2.4 (0.054) 2.9 (0.121) 2.9 (0.042) <0.0001
140–159 3.2 (0.015) 3.2 (0.025) 3.2 (0.024) 2.6 (0.053) 3.4 (0.075) 3.0 (0.038) <0.0001
160–179 3.3 (0.020) 3.3 (0.033) 3.3 (0.032) 2.7 (0.081) 3.5 (0.080) 3.3 (0.057) <0.0001
≥180 3.4 (0.034) 3.4 (0.055) 3.5 (0.058) 3.0 (0.153) 3.9 (0.131) 3.5 (0.096) <0.0001
P value <0.0001 <0.0001 <0.0001 <0.0001 0.0005 <0.0001
DBP (mmHg)
<90 3.0 (0.013) 3.1 (0.022) 3.1 (0.021) 2.4 (0.037) 3.0 (0.081) 2.9 (0.031) <0.0001
90–99 3.3 (0.016) 3.3 (0.028) 3.3 (0.027) 2.8 (0.074) 3.4 (0.073) 3.1 (0.045) <0.0001
100–109 3.4 (0.026) 3.4 (0.047) 3.4 (0.041) 2.9 (0.141) 3.9 (0.098) 3.4 (0.069) <0.0001
≥110 3.5 (0.049) 3.5 (0.086) 3.6 (0.080) 3.9 (0.311) 3.5 (0.169) 3.6 (0.151) 0.5736
P value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
RR (mmHg)
uncontrolled∗ 3.4 (0.014) 3.3 (0.019) 3.3 (0.018) 2.7 (0.042) 3.5 (0.050) 3.1 (0.029) <0.0001
controlled∗∗ 3.0 (0.012) 3.0 (0.034) 3.0 (0.027) 2.4 (0.050) 2.9 (0.115) 2.9 (0.040) <0.0001
P value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
∗SBP/DBP ≥140/90 in non-diabetic and ≥130/80 in diabetic patients, ∗∗<140/90 in non-diabetic and <130/80 in diabetic patients.
Table 7: Blood pressure and HDL-Cholesterol (mmol/L ± SD, adjusted for age, gender, and diabetes).
Total
(N = 11,849)
Northern Europe
(N = 3,787)
Southern Europe
(N = 4,924)
North America
(N = 909)
Middle East
(N = 477)
Asia
(N = 1,752) P value
SBP (mmHg)
<120 1.3 (0.025) 1.4 (0.051) 1.2 (0.044) 1.4 (0.065) 1.1 (0.135) 1.3 (0.053) 0.0498
120–139 1.3 (0.008) 1.4 (0.015) 1.3 (0.012) 1.3 (0.024) 1.1 (0.054) 1.3 (0.018) <0.0001
140–159 1.3 (0.007) 1.5 (0.011) 1.3 (0.010) 1.3 (0.024) 1.2 (0.034) 1.3 (0.017) <0.0001
160–179 1.3 (0.009) 1.4 (0.014) 1.3 (0.014) 1.3 (0.035) 1.1 (0.035) 1.3 (0.025) <0.0001
≥180 1.3 (0.016) 1.5 (0.025) 1.2 (0.026) 1.3 (0.070) 1.0 (0.059) 1.3 (0.045) <0.0001
P value 0.3309 0.0558 0.1317 0.3366 0.6608 0.7711
DBP (mmHg)
<90 1.3 (0.005) 1.4 (0.010) 1.3 (0.009) 1.3 (0.017) 1.2 (0.038) 1.3 (0.014) <0.0001
90–99 1.3 (0.007) 1.4 (0.012) 1.3 (0.011) 1.3 (0.033) 1.2 (0.033) 1.3 (0.020) <0.0001
100–109 1.3 (0.011) 1.4 (0.016) 1.2 (0.014) 1.3 (0.047) 1.1 (0.034) 1.2 (0.024) <0.0001
≥110 1.3 (0.033) 1.6 (0.057) 1.2 (0.052) 1.4 (0.208) 1.0 (0.114) 1.2 (0.102) <0.0001
P value 0.0222 0.0013 0.0904 0.7721 0.0188 0.6265
RR (mmHg)
uncontrolled∗ 1.3 (0.006) 1.5 (0.008) 1.3 (0.008) 1.3 (0.019) 1.1 (0.022) 1.3 (0.013) <0.0001
controlled∗∗ 1.3 (0.006) 1.4 (0.016) 1.3 (0.013) 1.3 (0.023) 1.1 (0.054) 1.3 (0.019) <0.0001
P value 0.1340 0.0916 0.1632 0.9361 0.8361 0.8030
∗SBP/DBP ≥140/90 in non-diabetic and ≥130/80 in diabetic patients, ∗∗<140/90 in non-diabetic and <130/80 in diabetic patients.
HbA1c, and CRP, whereas there was no association between
HDL-cholesterol and blood pressure levels. Furthermore,
the presence of diabetes was associated with an elevated
SBP only. The observed associations between blood pressure
levels and metabolic parameters were consistent across all 5
geographic regions, even though some associations were not
signiﬁcant, especially in regions with a low sample size for
individual parameters, such as the Middle East, Asia, and—
partly—North America. Based on the data presented herein,
it appears diﬃcult to draw any ﬁrm conclusions on stronger
and weaker associations of individual cardiometabolic pa-
rameters with blood pressure for some regions as compared
to the overall population or the European region. Further-
more, regional samples cannot be necessarily considered as8 Cardiology Research and Practice
Table 8: Blood pressure and triglycerides (mmol/L ± SD, adjusted for age, gender, and diabetes).
Total
(N = 12,601)
Northern Europe
(N = 4,049)
Southern Europe
(N = 5,095)
North America
(N = 910)
Middle East
(N = 504)
Asia
(N = 2043) P value
SBP (mmHg)
<120 1.5 (0.037) 1.6 (0.078) 1.6 (0.068) 1.5 (0.102) 1.3 (0.206) 1.7 (0.076) 0.4212
120–139 1.7 (0.017) 1.8 (0.033) 1.6 (0.027) 1.8 (0.054) 1.7 (0.120) 1.8 (0.038) <0.0001
140–159 1.8 (0.014) 1.9 (0.025) 1.7 (0.023) 1.7 (0.054) 2.1 (0.075) 1.9 (0.036) <0.0001
160–179 1.9 (0.020) 2.0 (0.033) 1.8 (0.033) 1.7 (0.085) 2.2 (0.082) 2.0 (0.055) <0.0001
≥180 1.9 (0.034) 2.0 (0.055) 1.8 (0.057) 1.9 (0.157) 2.3 (0.134) 2.2 (0.097) 0.0054
P value <0.0001 <0.0001 <0.0001 0.1658 0.0039 0.0008
DBP (mmHg)
<90 1.7 (0.012) 1.8 (0.021) 1.6 (0.020) 1.7 (0.037) 1.7 (0.078) 1.8 (0.028) <0.0001
90–99 1.9 (0.016) 2.0 (0.028) 1.8 (0.026) 1.9 (0.074) 2.2 (0.073) 1.9 (0.042) <0.0001
100–109 1.9 (0.027) 2.0 (0.050) 1.8 (0.044) 2.0 (0.154) 2.3 (0.108) 2.1 (0.073) <0.0001
≥110 1.9 (0.053) 1.8 (0.089) 1.9 (0.084) 1.9 (0.342) 2.4 (0.180) 2.3 (0.161) 0.0073
P value <0.0001 <0.0001 <0.0001 0.0469 0.0012 <0.0001
RR (mmHg)
uncontrolled∗ 1.9 (0.014) 2.0 (0.018) 1.7 (0.017) 1.8 (0.043) 2.1 (0.050) 1.9 (0.028) <0.0001
controlled∗∗ 1.7 (0.011) 1.7 (0.033) 1.6 (0.027) 1.7 (0.050) 1.7 (0.115) 1.8 (0.037) 0.0024
P value <0.0001 <0.0001 <0.0001 0.4255 0.0025 0.0081
∗SBP/DBP ≥140/90 in non-diabetic and ≥130/80 in diabetic patients, ∗∗<140/90 in non-diabetic and <130/80 in diabetic patients.
Table 9: Blood pressure and CRP (mg/dL ± SD, adjusted for age, and gender).
Total
(N = 2,493)
Northern Europe
(N = 1,207)
Southern Europe
(N = 943)
North America
(N = 109)
Middle East
(N = 112)
Asia
(N = 122) P value
SBP (mmHg)
<120 0.7 (0.090) 0.8 (0.131) 0.8 (0.160) 0.6 (0.284) 0.6 (0.576) 0.1 (0.304) 0.3399
120–139 0.7 (0.037) 0.7 (0.062) 0.8 (0.053) 0.4 (0.154) 0.4 (0.286) 0.4 (0.139) 0.0141
140–159 0.9 (0.030) 1.0 (0.043) 0.9 (0.050) 0.5 (0.146) 1.1 (0.145) 0.5 (0.133) 0.0009
160–179 1.1 (0.041) 1.1 (0.055) 1.1 (0.070) 0.5 (0.250) 0.9 (0.168) 0.6 (0.219) 0.0196
≥180 1.1 (0.066) 1.3 (0.087) 0.8 (0.117) 1.1 (0.301) 0.8 (0.230) 0.3 (0.500) 0.0097
P value <0.0001 <0.0001 0.0520 0.0356 0.4130 0.3783
DBP (mmHg)
<90 0.8 (0.027) 0.8 (0.038) 0.8 (0.043) 0.4 (0.112) 0.9 (0.164) 0.4 (0.114) <0.0001
90–99 1.0 (0.035) 1.1 (0.049) 0.9 (0.058) 0.6 (0.187) 1.1 (0.150) 0.6 (0.155) 0.0022
100–109 1.1 (0.050) 1.3 (0.072) 1.0 (0.078) 1.0 (0.293) 0.8 (0.193) 0.4 (0.253) 0.0013
≥110 1.0 (0.091) 1.2 (0.130) 0.8 (0.158) 0.6 (0.424) 0.9 (0.338) 0.9 (0.456) 0.3130
P value <0.0001 <0.0001 0.4665 0.0056 0.5488 0.1511
RR (mmHg)
uncontrolled∗ 1.0 (0.028) 1.1 (0.031) 0.9 (0.037) 0.6 (0.114) 0.9 (0.096) 0.5 (0.106) <0.0001
controlled∗∗ 0.8 (0.026) 0.7 (0.061) 0.8 (0.054) 0.4 (0.143) 0.6 (0.348) 0.4 (0.140) 0.0057
P value <0.0001 <0.0001 0.1596 0.2786 0.4071 0.1582
∗SBP/DBP ≥140/90 in non-diabetic and ≥130/80 in diabetic patients, ∗∗<140/90 in non-diabetic and <130/80 in diabetic patients.
ethnically/culturally homogenous and any regional analysis
mightbeconfoundedbydiﬀerencesinthegeneticsordietary
habits of study participants.
Overall, our data are consistent with ﬁndings from other
investigations,wheretheprevalenceofadditionalcardiomet-
abolic risk factors among hypertensive patients was as high
as 82% and was associated with poor blood control in the
United States [12]. Of interest, data from the large European
Global Cardiometabolic Risk Proﬁle in Patients with Hyper-
tension Disease (GOOD) survey in 3280 outpatients treatedCardiology Research and Practice 9
for or newly diagnosed with hypertension indicate that
the prevalence of cardiometabolic risk factors is higher in
Central Europe (Hungary) and Atlantic European Mainland
(Belgium, Germany, and the Netherlands) compared with
the Northwest (Norway, Sweden, and the United Kingdom)
and Mediterranean (Italy, Portugal, Slovenia, Spain, and
Turkey) regions [13]. Similarly to the GOOD Survey, only
one quarter of patients had controlled blood pressure in our
study [14].
Our results conﬁrm the signiﬁcant association between
systemic hypertension and other cardiometabolic risk fac-
tors, including visceral obesity, diabetes, and hyperlipide-
mia. Obviously, the vast majority of patients with arterial
hypertension are at multiple risk of cardiovascular disease.
Therefore, our data emphasize the statement of current joint
guidelines of the European Society of Hypertension and
European Society of Cardiology concerning an intensiﬁed
diagnostic and therapeutic measures in patients with an el-
evated SBP and DBP [8].
Reasons for the observed association between increasing
blood pressure and the presence of cardiometabolic risk fac-
tors remain to be determined. It is a subject of an ongoing
debate, whether patients with an elevated SBP and DBP
simply more frequently have an unfavorable cardiometabolic
risk proﬁle with poorly treated cardiovascular parameters or
whether there is a causal relationship between a high sys-
temic blood pressure and the deterioration of multiple car-
diometabolic markers. The intra-abdominal obesity and re-
cently discovered endogenous gland activity of adipose tissue
producing various hormones and cytokines, such as angiot-
ensinogen, insulin, resistin, lipoprotein lipase, leptin, lactate,
plasminogen activator inhibitor, adipsin, and interleukin,
seem to play a central role in the development of disad-
vantageous cardiometabolic proﬁle and may represent the
causal link between arterial hypertension, atherogenic dys-
lipidemia,diabetes,thrombosis,andinﬂammation[15].This
hypothesis is further supported by the mandatory presence
of abdominal obesity in the deﬁnition of potentially detri-
mental metabolic syndrome [16, 17]. Other possible reasons
include organ damage as a consequence of hypertension
which may lead to potentiation of other cardiometabolic risk
factors. In addition, visceral obesity, hypertriglyceridemia,
and low HDL-cholesterol levels were associated with resis-
tance to antihypertensive therapy in the GOOD survey
[18].
Proinﬂammatory mechanisms are thought to be a hall-
markofthecardiovasculardiseaseprocess,notablyindisease
states such as hypertension. These ﬁndings are often exac-
erbated by the increasing prevalence of obesity worldwide.
Obesity is often accompanied by high plasma levels of non-
esteriﬁed fatty acids that cause insulin resistance in skeletal
muscle and overload the liver with lipids, producing fatty
liver and atherogenic dyslipidemia [19]. Fat accumulation
in the liver may also stimulate hepatic cytokine production
and lead to higher levels of proinﬂammatory markers. Taken
together, the abnormal proinﬂammatory state leads to a
worsening of metabolic control, abnormal vascular function,
and eventually cardiovascular and renal diseases [20].
Lifestyle changes, including an increased prevalence of
obesity and the metabolic syndrome contribute to the inci-
dence of hypertension [21, 22]. At the environmental level,
barriers to healthy lifestyles include lack of access to exercise
facilities at work or in the community, lack of bicycle and
walking paths, and high traﬃc and crime in urban settings
which prevent access to safe walking areas. Seasonal varia-
tion, market availability, and aﬀordability of fresh fruits and
vegetables in small urban stores are issues, thus multilevel
approaches incorporating both individual and policy level
changesareadvocated.Thesevariationsaremagniﬁedwithin
certain ethnic and geographical situations. Nevertheless,
despitetheuncertaintyaboutthecausalrelationshipbetween
an elevated SBP and DBP and the presence of cardiometa-
bolic risk factors, the association appeared to be signiﬁcant
and consistent across various continents and ethnicities in
our study. The beneﬁts of a multidimensional approach
inﬂuencing antioxidative, antiinﬂammatory, or antithrom-
botic pathway on cardiovascular outcomes were repeatedly
demonstrated in the context of hypertension management
[23]. Consequently, a systematic assessment of the global
cardiovascular risk and a risk-based approach to antihyper-
tensive therapy shall be mandated in all patients with arterial
hypertension.
4.1. Strengths and Limitations of Our Study. The strengths
of our study include the prospective enrollment of a large
sample of treated hypertensive patients and the collection of
detailed information on systemic blood pressure and cardi-
ometabolic parameters.
One study limitation is the fact that the numbers of
enrolled patients diﬀer substantially between the 5 regions.
Therefore, the regional comparisons and P-values should be
interpreted with caution. Neither a uniform methodology
nor a central laboratory was used for measurements of blood
pressure and cardiometabolic parameters. Thus, differences
in region-speciﬁc techniques and measurements may have
inﬂuenced the comparability of results. Another study lim-
itation is the fact that the present analysis of lipid measure-
ments was not adjusted for statin use. However, the analysis
was adjusted for age and, therefore, for age-dependent rise
of LDL-cholesterol and triglycerides, and indirectly also for
statin use because the elderly more often receive statin treat-
ment. Finally, our study was not designed to explore reasons
for the observed association between an elevated blood pres-
sure and cardiometabolic risk factors.
5. Conclusions
An elevated SBP and DBP, but also uncontrolled hyperten-
sion, are associated with an increase in cardiometabolic risk,
independently of the geographic region. These ﬁndings not
only highlight the importance of a thorough risk-stratiﬁca-
tionofpatientswitharterialhypertension,butalsotheneces-
sity of treating concomitant cardiometabolic risk factors in
order to decrease the overall cardiovascular risk of patients
with arterial hypertension.10 Cardiology Research and Practice
References
[ 1 ]A .D .L o p e z ,C .D .M a t h e r s ,M .E z z a t i ,D .T .J a m i s o n ,a n dC .
J. Murray, “Global and regional burden of disease and risk
factors, 2001: systematic analysis of population health data,”
Lancet, vol. 367, no. 9524, pp. 1747–1757, 2006.
[2] P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K.
Whelton, and J. He, “Global burden of hypertension: analysis
of worldwide data,” Lancet, vol. 365, no. 9455, pp. 217–223,
2005.
[3] P. Bramlage, M. B¨ ohm, M. Volpe et al., “A global perspective
on blood pressure treatment and control in a referred cohort
of hypertensive patients,” Journal of Clinical Hypertension,
vol. 12, no. 9, pp. 666–677, 2010.
[4] G. Whitlock, S. Lewington, P. Sherliker, R. Clarke, J. Ember-
son, and J. Halsey, “Body-mass index and cause-speciﬁc mor-
tality in 900 000 adults: collaborative analyses of 57 prospec-
tive studies,” The Lancet, vol. 373, no. 9669, pp. 1083–1096,
2009.
[5] J. St-Pierre, I. Lemieux, P. Perron et al., “Relation of the “hy-
pertriglyceridemic waist” phenotype to earlier manifestations
of coronary artery disease in patients with glucose intolerance
and type 2 diabetes mellitus,” American Journal of Cardiology,
vol. 99, no. 3, pp. 369–373, 2007.
[6] V. Manninen, L. Tenkanen, P. Koskinen et al., “Joint eﬀects of
serum triglyceride and LDL cholesterol and HDL cholesterol
concentrations on coronary heart disease risk in the Helsinki
Heart Study. Implications for treatment,” Circulation, vol. 85,
no. 1, pp. 37–45, 1992.
[7] C. Nielson, T. Lange, and N. Hadjokas, “Blood glucose and
coronary artery disease in nondiabetic patients,” Diabetes
Care, vol. 29, no. 5, pp. 998–1001, 2006.
[8] “2003 European Society of Hypertension-European Society of
Cardiology guidelines for the management of arterial hyper-
tension,”JournalofHypertension,vol.21,no.6,pp.1011–1153,
2003.
[9] A. M. Kuklinska, B. Mroczko, W. J. Musial et al., “Inﬂuence of
atorvastatin on blood pressurecontrol in treated hypertensive,
normolipemic patients. An open, pilot study,” Blood Pressure,
vol. 19, no. 4, pp. 260–266, 2010.
[10] B. Hansel, X. Girerd, D. Bonnefont-Rousselot et al., “Blood
pressure-lowering response to amlodipine as a determinant
of the antioxidative activity of small, dense HDL3,” American
Journal of Cardiovascular Drugs, vol. 11, no. 5, pp. 317–325,
2011.
[11] M. B¨ ohm, M. Thoenes, N. Danchin, P. Bramlage, P. La Puerta,
and M. Volpe, “Association of cardiovascular risk factors
with microalbuminuria in hypertensive individuals: the i-
SEARCHglobalstudy,”JournalofHypertension,vol.25,no.11,
pp. 2317–2324, 2007.
[12] D. A. Belletti, C. Zacker, and J. Wogen, “Eﬀect of cardiomet-
abolic risk factors on hypertension management: a cross-
sectional study among 28 physician practices in the United
States,” Cardiovascular Diabetology, vol. 9, article 7, 2010.
[13] C. Farsang, L. Naditch-Brule, S. Perlini, W. Zidek, and S. E.
Kjeldsen, “Inter-regional comparisons of the prevalence of
cardiometabolic risk factors in patients with hypertension in
Europe: the GOOD survey,” Journal of Human Hypertension,
vol. 23, no. 5, pp. 316–324, 2009.
[14] S. E. Kjeldsen, L. Naditch-Brule, S. Perlini, W. Zidek, and
C. Farsang, “Increased prevalence of metabolic syndrome in
uncontrolled hypertension across Europe: the Global Cardi-
ometabolic Risk Proﬁle in Patients with hypertension disease
survey,” Journal of Hypertension, vol. 26, no. 10, pp. 2064–
2070, 2008.
[15] J. P. Despr´ es, “Intra-abdominal obesity: an untreated risk fac-
tor for Type 2 diabetes and cardiovascular disease,” Journal of
endocrinological investigation., vol. 29, no. 3, supplement,
pp. 77–82, 2006.
[ 1 6 ]G .d eS i m o n e ,M .H .O l s e n ,K .W a c h t e l le ta l . ,“ C l u s t e r so f
metabolic risk factors predict cardiovascular events in hyper-
tension with target-organ damage: the LIFE study,” Journal of
Human Hypertension, vol. 21, no. 8, pp. 625–632, 2007.
[17] J. M. Torpy, C. Lynm, and R. M. Glass, “JAMA patient page.
The metabolic syndrome,” Journal of the American Medical
Association, vol. 295, no. 7, p. 850, 2006.
[18] W. Zidek, L. Naditch-Brˆ ul´ e, S. Perlini, C. Farsang, and S.
E. Kjeldsen, “Blood pressure control and components of the
metabolic syndrome: The good survey,” Cardiovascular Diabe-
tology, vol. 8, article 51, 2009.
[19] M.A.E.AnnaDiehl,“Nonalcoholicsteatosisandsteatohepati-
tis IV. Nonalcoholic fatty liver disease abnormalities in macro-
phagefunctionandcytokines,”AmericanJournalofPhysiology,
vol. 282, no. 1, pp. G1–G5, 2002.
[20] S.M.Grundy,“Inﬂammationhypertension,andthemetabolic
syndrome,” Journal of the American Medical Association,
vol. 290, no. 22, pp. 3000–3002, 2003.
[21] K. J. Greenlunda, M. L. Daviglus, and J. B. Croft, “Dif-
ferences in healthy lifestyle characteristics between adults
with prehypertension and normal blood pressure,” Journal of
Hypertension, vol. 27, no. 5, pp. 955–962, 2009.
[ 2 2 ] N .T .N g u y e n ,C .P .M a g n o ,K .T .L a n e ,M .W .H i n o j o s a ,a n dJ .
S. Lane, “Association of hypertension, diabetes, dyslipidemia,
and metabolic syndrome with obesity: ﬁndings from the
national health and nutrition examination survey, 1999 to
2004,” Journal of the American College of Surgeons, vol. 207,
no. 6, pp. 928–934, 2008.
[23] C. Farsang, L. Naditch-Brule, A. Avogaro et al., “Where are
we with the management of hypertension? From science to
clinical practice,” Journal of Clinical Hypertension, vol. 11,
no. 2, pp. 66–73, 2009.